Clinical Relevance of Small Airways Disease in Severe Asthma Patients Treated With Anti-InterLeukin-5 Therapy

Frisius Medisch Centrum110 enrolled

Overview

The aim of this research is to investigate the extent and clinical relevance of small airways disease in severe eosinophilic asthma patients treated with anti-IL5/5R therapy.

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Asthma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Severe asthma patients treated with anti-IL5/5R therapy (i.e. mepolizumab, benralizumab, reslizumab) for at least 4 months. Exclusion Criteria: * No information about lung function at baseline, or after both 4 months and 12 months. * No information about clinical response (i.e. number of exacerbations, reduction of mOCS/ maintenance oral corticosteroid dose, ACQ, AQLQ) after both 4 months and 12 months. * Treatment with another anti-IL5/5R therapy before

Locations (1)

Medical Center Leeuwarden

Leeuwarden, Netherlands

RECRUITING

Outcomes

Primary Outcomes

Is change in FEF25-75 during anti-IL5/5R treatment associated with change in asthma control (measured with the asthma control questionnaire -ACQ-) in severe eosinophilic asthma patients after 4 months and after 12 months treatment?

Time frame: 4 months and 12 months

Central Contacts

Akke Nynke van der Meer, MD PhD

CONTACT

003158-2866666 a.n.van.der.meer@mcl.nl

Ilse Boudewijn, MD

CONTACT

003150-3616161 i.m.boudewijn@umcg.nl

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.